CCEL
Cryo-Cell International, Inc.
CCEL trails on the overall score without a compensating advantage in the available component scores.
UNH
UnitedHealth Group Incorporated
UNH has the edge over CCEL overall, supported by lower modeled downside and stronger modeled upside.
CCEL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Weak |
CCEL's revenue and cash flow are currently stable, but its profitability and balance sheet are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CCEL PE Valuation
CCEL has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 68x next year's earnings.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CCEL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Decline | |
| -- | |
| Limited | |
| -- |
Analysts expect CCEL to return to profit, with revenue declining.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CCEL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.08 | — |
| Q3 2026 | -$0.22 | -$0.15 |
| Q2 2026 | -$0.29 | -$0.26 |
| Q1 2026 | -$0.32 | -3300% |
| Q4 2025 | -$0.30 | -700% |
| Q3 2025 | -$0.07 | +$0.99 |
| Q2 2025 | -$0.03 | +$1.08 |
| Q1 2025 | $0.01 | +$1.17 |
| Q4 2024 | $0.05 | +$1.19 |
CCEL is still losing money, but far less than before: $0.22 per share over the past year, against $1.16 at its worst in early 2024.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CCEL on earnings quality, reporting a profit while its opponent remains loss making.
CCEL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.8M | 0% |
| Q2 2026 | $7.8M | -1.9% |
| Q1 2026 | $7.7M | -3.6% |
| Q4 2025 | $7.8M | -2.3% |
| Q3 2025 | $7.8M | -3% |
| Q2 2025 | $7.9M | -1.4% |
| Q1 2025 | $8M | +1.5% |
| Q4 2024 | $8M | +1.9% |
CCEL's revenue has held roughly level: $8M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 28% | +3.8 points |
| Q2 2026 | 15% | -3.4 points |
| Q1 2026 | 10% | -3.3 points |
| Q4 2025 | -51% | -49 points |
| Q3 2025 | 24% | +7.1 points |
| Q2 2025 | 19% | +1.5 points |
| Q1 2025 | 13% | +2.8 points |
| Q4 2024 | -1.5% | +204 points |
CCEL has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over CCEL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
CCEL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1M | -58% |
| Q2 2026 | $1.8M | +181% |
| Q1 2026 | $584.8K | -34% |
| Q4 2025 | $1.2M | -44% |
| Q3 2025 | $2.5M | +11% |
| Q2 2025 | $644.6K | +2891% |
| Q1 2025 | $892K | +$1.7M |
| Q4 2024 | $2.1M | +32% |
CCEL still generates free cash flow, though less than at its 2020 peak: $5M over the past year.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
CCEL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +9.7K shares |
| 1 year | -0.1% | -8.5K shares |
| 3 years | -3.3% | -277K shares |
| 5 years | -7.2% | -627K shares |
| Available history | -4.1% | -347K shares |
CCEL has 8M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $80,883 |
| Q2 2025 | $88,619 |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $16,400 |
| Q2 2024 | $1.2M |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CCEL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CCEL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.5x | High |
| Q2 2026 | 10.3x | High |
| Q1 2026 | 7.7x | High |
| Q4 2025 | 6.0x | High |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 1.8x | Healthy |
| Q4 2024 | 2.0x | Healthy |
CCEL's net debt is about 6.5 years of its operating earnings (EBITDA), up from 1.6 years a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH has the edge over CCEL on leverage, with a lower net debt burden relative to earnings.
CCEL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.8 | Neutral |
| Stochastic | 88.0 | Overbought |
CCEL's weekly RSI is 67 (neutral) and its Stochastic is 88 (overbought).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CCEL PE vs Healthcare Sector
| Metric | CCEL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CCEL has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CCEL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.62 | 17% above |
| 20 week MA | $4.16 | 30% above |
| 50 week MA | $3.75 | 44% above |
| 100 week MA | $4.69 | 15% above |
| 200 week MA | $5.37 | 0.6% above |
CCEL has the edge over UNH on trend strength, trading above more of its moving averages.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
CCEL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.22 | $7.50 | +3.9% |
| 2021 | $7.50 | $12.4 | +65% |
| 2022 | $12.4 | $4.30 | -65% |
| 2023 | $4.30 | $5.75 | +34% |
| 2024 | $5.75 | $7.72 | +34% |
| 2025 | $7.72 | $3.50 | -55% |
| 2026 YTD | $3.50 | $5.40 | +54% |
CCEL has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.